Two-year Outcome of Turkish Patients Treated with Zotarolimus Versus Paclitaxel Eluting Stents in an Unselected Population with Coronary Artery Disease in the Real World: A Prospective Non-randomized Registry in Southern Turkey
dc.authorid | Muderrisoglu, Haldun/0000-0002-9635-6313 | |
dc.authorid | Pekdemir, Hasan/0000-0002-4913-5120; | |
dc.authorwosid | Muderrisoglu, Haldun/AAG-8233-2020 | |
dc.authorwosid | Pekdemir, Hasan/ABI-6096-2020 | |
dc.authorwosid | cicek, davran/AAC-8036-2020 | |
dc.authorwosid | Altay, Hakan/AAE-1392-2021 | |
dc.contributor.author | Cicek, Davran | |
dc.contributor.author | Pekdemir, Hasan | |
dc.contributor.author | Haberal, Cevahir | |
dc.contributor.author | Kalay, Nihat | |
dc.contributor.author | Binici, Suleyman | |
dc.contributor.author | Altay, Hakan | |
dc.contributor.author | Muderrisoglu, Haldun | |
dc.date.accessioned | 2024-08-04T20:32:42Z | |
dc.date.available | 2024-08-04T20:32:42Z | |
dc.date.issued | 2011 | |
dc.department | İnönü Üniversitesi | en_US |
dc.description.abstract | Background: Our purpose was to investigate the clinical outcomes of Zotarolimus- and Paclitaxel-eluting stents in Turkish patients with coronary artery disease (CAD). In general, the outcome of drug-eluting stent (DES) placement has a proven efficacy in randomized trials. However, the difference in efficacy between the Zotarolimus and Paclitaxel-eluting stents in unselected Turkish patients is controversial. Therefore, we investigated the clinical outcomes of these two drug-eluting stents in the real-world. Methods: We created a registry and prospectively analyzed data on a consecutive series of all patients who presented to our institution with symptomatic coronary artery disease between February 2005 and March 2007 and who were treated with the zotarolimus- or the paclitaxel-eluting stent. The follow-up period was approximately two years. The primary end-point was major cardiac events, and the secondary end-point was definite stent thrombosis. Informed consent was obtained from all subjects, and the study protocol was approved by the local ethical committee. Results: In total, 217 patients were treated with either the zotarolimus-eluting stent (n = 116) or the paclitaxel-eluting stent (n = 101). The lesions in the 2 arms of the study were treated similarly by conventional technique. At 24-month follow-up the paclitaxel-eluting stent group showed significantly higher non-Q wave myocardial infarction (2.6% vs 5.9%, p: 0.02), Q wave myocardial infarction (1.7% vs 5.9%, p: 0.049), coronary artery binding graft surgery (2.6% vs 6.9%, p: 0.002), and late stent thrombosis (1.7% vs 3.9%, p: 0.046). Conclusions: Zotarolimus-eluting stents demonstrated better clinical outcomes than Paclitaxel- eluting stents in a daily routine practice of coronary intervention in an unselected Turkish population. | en_US |
dc.identifier.doi | 10.7150/ijms.8.68 | |
dc.identifier.endpage | 73 | en_US |
dc.identifier.issn | 1449-1907 | |
dc.identifier.issue | 1 | en_US |
dc.identifier.pmid | 21234271 | en_US |
dc.identifier.scopus | 2-s2.0-79751518062 | en_US |
dc.identifier.scopusquality | Q2 | en_US |
dc.identifier.startpage | 68 | en_US |
dc.identifier.uri | https://doi.org/10.7150/ijms.8.68 | |
dc.identifier.uri | https://hdl.handle.net/11616/95252 | |
dc.identifier.volume | 8 | en_US |
dc.identifier.wos | WOS:000287604200008 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | Ivyspring Int Publ | en_US |
dc.relation.ispartof | International Journal of Medical Sciences | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | coronary artery disease | en_US |
dc.subject | drug-eluting stent | en_US |
dc.subject | major adverse cardiac event | en_US |
dc.subject | stent thrombosis | en_US |
dc.title | Two-year Outcome of Turkish Patients Treated with Zotarolimus Versus Paclitaxel Eluting Stents in an Unselected Population with Coronary Artery Disease in the Real World: A Prospective Non-randomized Registry in Southern Turkey | en_US |
dc.type | Article | en_US |